#0589 🔬Time to Response in PsA Domains: Secukinumab ➡️Post-hoc analyses, n=1366 🔑Median time (wks) to MCID 👇 🔴Systemic inflammation <2 🔴MSK: ~4 wks (enthesitis~12) 🔴Fatigue~7–8 🔴PASI75~8–12; nails ~24 🩺 Rapid MSK & QoL benefits precede skin/nail #ACR24 @RheumNow https://t.co/WfqkryA1CC

• https://x.com/CaoilfhionnMD/status/1857827721856037222/photo/1

Data from the study by Dr. Aguilar et al showed that high dose NSAID use was not assoc'd with incident HTN in their cohort of early axSpA patients. Shows important role of NSAIDs in #axSpA but still should be used judiciously @RheumNow #ACR24 abs540 @rheum_cat @rheumarhyme https://t.co/LK5yFZynu4

• https://x.com/RHEUMarampa/status/1857827589999526276/photo/1

Switching vs cycling - which is better? In PsA & axSpA, a real-world analysis shows that switching to IL-17Ai after TNFi discontinuation may lead to similar or better outcomes compared to cycling to another TNFi. Data from the CorEvitas PsA/SpA Registry. Abstr#0585.… https://t.co/AJP4NBjmzr

• https://x.com/i/web/status/1857827218912849961

De Lorenzis et al. MMF in LcSSc. Target Trial Emulation. 1435 patients. Incidence vasodilator treatment escalation over 41 months, 1/100py in MMF vs 7.3/100py in controls. @RheumNow #ACR24 Abstr#0688 https://t.co/D3qTUHyIIc https://t.co/6azvaS0ElL

• Mycophenolate Mofetil Treatment in Limited Cutaneous Systemic Sclerosis Reduces…
• https://x.com/RichardPAConway/status/1857826212040573293/photo/1

Galloway et al report OCP/HRT use in RA is not associated with VTE in UK population based study. Increased risk by having RA, HR 1.52. Risk OCP HR 1.43, HRT HR 2.32 - neither statistical significant but very wide CI's! Hmm... @RheumNow #ACR24 Abstr#0134 https://t.co/CZNoRfYWe8 https://t.co/uC6jA9lcX9

• Use of Oral Contraceptives in Females with Rheumatoid Arthritis Is Not Associat…
• https://x.com/RichardPAConway/status/1857825456986476845/photo/1

The risk of discontinuing first line biologics was twice higher in non-radiographic female patients compared to males. Abstr#0572 @RheumNow #ACR24 https://t.co/1tQUhsbqUu

• https://x.com/synovialjoints/status/1857825346197852220/photo/1

Dhir et al. RCT of increasing folic acid from 5-10mg per week to 15-35mg per week if MTX intolerance. No benefit! Although significant placebo response and folic acid is relatively benign. @RheumNow #ACR24 Abstr#0525 https://t.co/D3yfV6a8t6 https://t.co/QpDa1alvMz

• Assess the Effect of Increasing the Dose of Folic Acid Supplementation in Patie…
• https://x.com/RichardPAConway/status/1857824199076884798/photo/1

Yokose et al. Population study using NHANES. Gout patients had 1.6 higher fold risk of gallstone disease. What? Why do we care? Well, GLP-1s associated with higher risk gallstones also... @RheumNow #ACR24 Abstr#0133 https://t.co/nf4R0hQe50 https://t.co/wDrEDeNbpT

• The Association Between Gout and Gallstone Disease: US General Population Analy…
• https://x.com/RichardPAConway/status/1857824198754029764/photo/1

🧬 #SLE patients show major community mobility limits: 50% don't leave their neighborhood weekly without help. Life Space Assessment finds lower mobility vs. other chronic conditions. Better mobility linked to higher SES & lower disease activity. @RheumNow #ACR24 abst#0145 https://t.co/2sfXNlJ9JD

• https://x.com/bella_mehta/status/1857823695638564985/photo/1

Data from the French DESIR cohort reveals no significant link between high-dose NSAID use and incident hypertension in patients with axial spondyloarthritis. Two thirds were high dose NSAID users at baseline. Incident hypertension occurred in 11% individuals during follow-up.… https://t.co/EAICDwzxNT

• https://x.com/i/web/status/1857823444974374951

Courvoisier et al. JAK-pot study analysis. Which therapies work quicker in RA? JAKi (as expected) and TNFi (what!?) faster than IL6 and abatacept. @RheumNow #ACR24 Abstr#0501 https://t.co/7DPPwHlqpP https://t.co/3mOJ62hZhp

• How Fast Do JAK-inhibitors, TNF-inhibitors, Abatacept and IL-6 Inhibitors Act i…
• https://x.com/RichardPAConway/status/1857823192204677592/photo/1

Shu et al. Rituximab followed by Telitacicept in refractory/severe APS. Significantly fewer new clinical events in Telitacicept group over 24 weeks (1/21 vs. 6/20) @RheumNow #ACR24 Abstr#0129 https://t.co/hjUQkNNk5w https://t.co/QLQbZ3wQx0

• The Efficacy and Safety of Telitacicept Following Rituximab Immunotherapy on An…
• https://x.com/RichardPAConway/status/1857822940433363387/photo/1

#0585 🔬PsA/axSpA: TNFi Cycling v IL-17Ai Switch ➡️470 pts: Switchers to IL-17Ai had similar/better outcomes v TNFi cyclers @ 6 mo ➡️PsA: Switchers had improved arthritis/psoriasis(-5.0, p=0.02) ➡️axSpA: Switchers had improved fatigue(-9.4, p=0.01) #ACR24 @RheumNow

🔍 Study on lupus & APS highlights key links! APS patients face higher rates of developing SLE, and vice versa. Notable predictors: females, lupus anticoagulant, and specific antibodies. These insights stress the need for vigilant monitoring in both. #ACR24 @RheumNow Abst#0119

Serrano-Combarro et al. Abatacept in RA-ILD. 343 patients. In 23.3% ILD progressed on abatacept. Is that good or bad? We need comparative studies! @RheumNow #ACR24 Abstr#0475 https://t.co/nUEDdjGguA https://t.co/sXEF72MafK

• Rheumatoid Arthritis - Progressive Interstitial Lung Disease with Abatacept: Da…
• https://x.com/RichardPAConway/status/1857821934110572580/photo/1